Literature DB >> 31235041

MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.

Wenfeng Fang1, Jiadi Gan1, Shaodong Hong1, Feng Lu2, Li Zhang3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31235041     DOI： 10.1016/j.jtho.2019.02.030

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  1 in total

1.  Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.

Authors:  Yun Shu; Hui Li; Hongjuan Shang; Jun Chen; Xiaoxing Su; Wei Le; Yan Lei; Liming Tao; Cailiang Zou; Wendy Wu
Journal:  Onco Targets Ther       Date:  2020-10-13       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.